PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Basit Öğe Kaydı
dc.authoridCavdar, Eyyup/0000-0001-5885-3047en_US
dc.authoriddeğerli, ezgi/0000-0002-8664-5701en_US
dc.authoridseber, selcuk erdogan/0000-0001-9081-2405en_US
dc.authoridKaraboyun, Kubilay/0000-0002-1783-8075en_US
dc.authoridŞenocak Taşçı, Elif/0000-0002-1686-1628en_US
dc.authoridyıldırım, hasan çağrı/0000-0003-3060-377Xen_US
dc.authoridAraz, Murat/0000-0002-4632-9501en_US
dc.authorscopusid56082620300en_US
dc.authorscopusid57226431644en_US
dc.authorscopusid57226624079en_US
dc.authorscopusid57431169800en_US
dc.authorscopusid54584820400en_US
dc.authorscopusid57204201984en_US
dc.authorscopusid57218910059en_US
dc.authorwosidCavdar, Eyyup/HDM-3862-2022en_US
dc.authorwosidOcak, Birol/AEC-2238-2022en_US
dc.authorwosidseber, selcuk erdogan/H-3327-2017en_US
dc.authorwosiddeğerli, ezgi/ADA-9893-2022en_US
dc.authorwosidKaraboyun, Kubilay/JDM-7868-2023en_US
dc.authorwosidŞenocak Taşçı, Elif/KBD-3048-2024en_US
dc.authorwosidyıldırım, hasan çağrı/HSH-7012-2023en_US
dc.contributor.authorAvci, Okan
dc.contributor.authorIriagac, Yakup
dc.contributor.authorCavdar, Eyyuep
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorAraz, Murat
dc.contributor.authorSakalar, Teoman
dc.contributor.authorDegerli, Ezgi
dc.date.accessioned2024-08-23T16:04:42Z
dc.date.available2024-08-23T16:04:42Z
dc.date.issued2023en_US
dc.departmentDüzce Üniversitesien_US
dc.description.abstractIntroduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (>= 65 years) with metastatic breast cancer patients were investigated.Materials and Methods: Among older patients receiving palbociclib and ribociclib, Geriatric 8 (G8) and Groningen Frailty Index were used to evaluate frailty status. Dose modifications, drug withdrawal and other serious adverse events (SAEs) were recorded and analyzed according to baseline patient characteristics.Results: A total of 160 patients from 28 centers in Turkey were included (palbociclib = 76, ribociclib = 84). Forty-three patients were >= 75 years of age. The most common cause of first dose modification was neutropenia for both drugs (97% palbociclib, 69% ribociclib). Liver function tests elevation (10%) and renal function impairment (6%) were also causes for ribociclib dose modification. Drug withdrawal rate was 3.9% for palbociclib and 6% for ribociclib. SAEs were seen in 11.8% of those taking palbociclib and 15.5% of those on riboclib. An ECOG performance status of >= 2 and being older than 75 years were associated with dose reductions. Severe neutropenia was more common in patients with non-bone-only metastatic disease, those receiving treatment third-line therapy or higher, coexistance of non-neutropenic hematological side effects (for ribociclib). Neutropenia was less common among patients with obesity.Discussion: Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged >= 75 years and/or with an ECOG performance status >= 2.en_US
dc.identifier.doi10.1016/j.jgo.2023.101604
dc.identifier.issn1879-4068
dc.identifier.issn1879-4076
dc.identifier.issue8en_US
dc.identifier.pmid37683369en_US
dc.identifier.scopus2-s2.0-85169931836en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.jgo.2023.101604
dc.identifier.urihttps://hdl.handle.net/20.500.12684/14313
dc.identifier.volume14en_US
dc.identifier.wosWOS:001078486200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Geriatric Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGeriatricsen_US
dc.subjectCDK 4/6 inhibitorsen_US
dc.subjectBreast canceren_US
dc.subjectAdverse eventsen_US
dc.subjectGroningen Frailty Indicatoren_US
dc.subjectGeriatric Assessmenten_US
dc.subjectEndocrine Therapyen_US
dc.subjectLetrozoleen_US
dc.subjectToolsen_US
dc.subjectG8en_US
dc.titlePROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu